|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | |  | | | | |  |  |  |  | | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  | | --- | | [Community Pharmacy England logo](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=02f1a885e5&e=d19e9fd41c) |  |  | | --- | | **Newsletter**  16th May 2025 | | | | | |  |  | | --- | --- | | |  | | --- | | The voice of community pharmacy (banner) | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **This newsletter - sent on Mondays, Wednesdays and Fridays - contains important information and resources to support community pharmacies across England.** | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **In this update: CPCF support and next steps discussed at Committee Meeting; End of antiviral medicine prescribing; Dispensing and Supply updates.** | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [A blue background with text  AI-generated content may be incorrect.](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=a19bcc680b&e=d19e9fd41c)  Community Pharmacy England met earlier this month in London, with Members reviewing the ongoing work to support implementation of the Community Pharmacy Contractual Framework (CPCF) settlement, alongside strategic work to bolster the sector’s position ahead of future negotiations.  During the meeting on 1st May 2025, updates were provided on the work to implement different elements of the CPCF settlement, with much of the detail discussed and scrutinised in the relevant subcommittee meetings held on 30th April.  A significant programme of work is underway to support pharmacy owners in preparing for the changes set out in the CPCF settlement and introducing the surrounding legal provisions to make those changes happen. We will also be holding the Government to account on its numerous commitments to improve things for the community pharmacy sector.  We have published a [full meeting summary](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=d809608ec8&e=d19e9fd41c) containing more information on this and other key topics discussed during the committee, including funding and margin, strategic projects, and pharmacy owner polling.    [A white and green text on a white background  AI-generated content may be incorrect.](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=973e949ec7&e=d19e9fd41c) | | |  |  |  | | --- | --- | | |  | | --- | | [**Read more about the meeting and our work**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=78a17b5a19&e=d19e9fd41c) | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **End of antiviral medicine prescribing for 2024/25 influenza season**  In light of surveillance data indicating that circulation of influenza in the community has returned to baseline levels, the Department of Health and Social Care has announced that antiviral medicines should no longer be prescribed or supplied against an FP10.  [**Learn more**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=80234896db&e=d19e9fd41c) | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | |  | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **Dispensing and Supply Updates**  **MHRA Drug Safety Update: Thiopurines and intrahepatic cholestasis of pregnancy**  The Medicines & Healthcare products Regulatory Agency (MHRA) has released a drug safety update on Thiopurines and intrahepatic cholestasis of pregnancy (ICP).  ICP has been rarely reported in patients treated with azathioprine products and is believed to be a risk applicable to all drugs in the thiopurine class (azathioprine, mercaptopurine and tioguanine). It tends to occur earlier in pregnancy than non drug-induced ICP, and elevated bile acid levels may not reduce with ursodeoxycholic acid.   [**Read the full drug safety update**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=281bfcf231&e=d19e9fd41c)  **Updated Dispensing and Supply Factsheet**  Our Dispensing and Supply Factsheet: Understanding the Single Activity Fee (SAF) has been updated to reflect the recent increase in the SAF to £1.46. It explains what the SAF is, with examples of items that attract multiple SAFs and those that do not.  *(See 'Single Activity Fee' mentioned at the top of the first table on the webpage via the link below)*  [**View the updated factsheet**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=015b3aadef&e=d19e9fd41c) | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  | | --- | --- | | |  | | --- | | [Community Pharmacy England banner](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=7d43731e4c&e=d19e9fd41c) | |  |  |  | | --- | --- | | |  | | --- | |  | | | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Twitter](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=83fe374a71&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Facebook](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=80042f4557&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [LinkedIn](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=9992df1ebb&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Website](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=c89652d7d3&e=d19e9fd41c) | | | | | | | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **Community Pharmacy England** Address: 14 Hosier Lane, London EC1A 9LQ Tel: 0203 1220 810 | Email: [comms.team@cpe.org.uk](mailto:comms.team@cpe.org.uk)  *Copyright © 2025 Community Pharmacy England, All rights reserved.*  You are receiving this email because you are subscribed to our newsletters. Please note Community Pharmacy England is the operating name of the Pharmaceutical Services Negotiating Committee (PSNC). | | | | |